Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2

Coronavirus causes a disease with high infectivity and pathogenicity, especially SARS in 2003, MERS in 2012, and COVID-2019 currently. The spike proteins of these coronaviruses are critical for host cell entry by receptors. Thus, searching for broad-spectrum anti-coronavirus candidates, such as spik...

Full description

Saved in:
Bibliographic Details
Published inPhytomedicine (Stuttgart) Vol. 85; p. 153364
Main Authors Yu, Shaopeng, Zhu, Yuying, Xu, Jiaruo, Yao, Guangtao, Zhang, Pei, Wang, Mengge, Zhao, Yongfang, Lin, Guoqiang, Chen, Hongzhuan, Chen, Lili, Zhang, Jiange
Format Journal Article
LanguageEnglish
Published Germany Elsevier GmbH 01.05.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Coronavirus causes a disease with high infectivity and pathogenicity, especially SARS in 2003, MERS in 2012, and COVID-2019 currently. The spike proteins of these coronaviruses are critical for host cell entry by receptors. Thus, searching for broad-spectrum anti-coronavirus candidates, such as spike protein inhibitors, is vital and desirable due to the mutations in the spike protein. In this study, a combination of computer-aided drug design and biological verification was used to discover active monomers from traditional Chinese medicine. Surface plasmon resonance (SPR) assays and NanoBit assays were used to verify the predicated compounds with their binding activities to spike proteins and inhibitory activities on the SARS-CoV-2 RBD/ACE2 interaction, respectively. Furthermore, an MTT assay was used to evaluate the cell toxicities of active compounds. As a result, glycyrrhizic acid (ZZY-44) was found to be the most efficient and nontoxic broad-spectrum anti-coronavirus molecule in vitro, especially, the significant effect on SARS-CoV-2, which provided a theoretical basis for the study of the pharmacodynamic material basis of traditional Chinese medicine against SARS-CoV-2 and offered a lead compound for further structural modification in order to obtain more effective candidate drugs against SARS-CoV-2. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors made equal contributions to this work.
ISSN:0944-7113
1618-095X
1618-095X
DOI:10.1016/j.phymed.2020.153364